For allergic conjunctivitis, can olopatadine (Patadine) ophthalmic drops be used together with ketorolac ophthalmic drops and oral diphenhydramine (Benadryl)?

Combination Therapy for Allergic Conjunctivitis

Yes, olopatadine (Patadine) ophthalmic drops can be safely used together with ketorolac ophthalmic drops and oral diphenhydramine (Benadryl), but this combination is not recommended because olopatadine alone is superior to ketorolac for allergic conjunctivitis, and adding oral Benadryl provides minimal additional benefit while increasing side effects. 1, 2, 3

Why This Combination Is Suboptimal

Olopatadine vs. Ketorolac Head-to-Head Evidence

• Olopatadine is significantly more effective than ketorolac for reducing ocular itching in allergic conjunctivitis, with superior symptom control demonstrated in multiple randomized trials. 2, 3
• In direct comparison studies, olopatadine reduced itching scores significantly more than ketorolac from day 2 through the end of treatment (p < 0.05). 2
• Ketorolac (a topical NSAID) provides only temporary itch relief and is inferior to dual-action agents like olopatadine, which combine antihistamine and mast-cell stabilizing properties. 1, 4
• Ketorolac showed a trend toward increased hyperemia compared to placebo in allergen challenge models, while olopatadine significantly reduced both itching and hyperemia (p < 0.0001). 3

The Problem with Adding Oral Benadryl

• Oral antihistamines like diphenhydramine are generally less effective than topical ophthalmic agents for ocular allergy symptoms, have slower onset of action, and do not address the local allergic response as effectively. 5, 1
• Oral antihistamines are associated with excessive drying of the tear film, which can worsen ocular discomfort and exacerbate symptoms in allergic conjunctivitis patients. 5, 1
• First-generation antihistamines like Benadryl cause significant sedation and anticholinergic effects (dry mouth, urinary retention, confusion), making second-generation agents preferable when systemic therapy is needed. 4

Safety Considerations for Ketorolac

• Ketorolac carries risks of corneal complications including corneal erosion, corneal thinning, epithelial breakdown, corneal ulcer, and even corneal perforation, particularly with prolonged use. 6
• The most frequent adverse events with ketorolac include transient stinging and burning (up to 40% of patients), ocular irritation, superficial keratitis, and corneal edema. 6

The Recommended Approach Instead

First-Line Monotherapy

• Start with olopatadine 0.1% (Patanol) one drop in each affected eye twice daily (6–8 hours apart) as monotherapy—this dual-action agent provides rapid relief within 3–30 minutes and is effective for both acute and chronic allergic conjunctivitis. 1, 7
• Olopatadine can be safely continued for up to 4 months without loss of efficacy. 7
• Refrigerating the olopatadine drops before instillation provides additional cooling comfort. 7

Adjunctive Non-Pharmacologic Measures

• Add cold compresses and refrigerated preservative-free artificial tears liberally to dilute ocular allergens and provide immediate symptomatic relief. 1
• Implement allergen-avoidance strategies: wear sunglasses outdoors, use hypoallergenic bedding, perform eyelid cleansing, and shower before bedtime. 1

When to Escalate (Not Add Ketorolac)

• If olopatadine alone does not control symptoms after 1–2 weeks, add a short course (1–2 weeks) of topical loteprednol etabonate, which has the lowest risk of intraocular pressure elevation among ocular corticosteroids. 1
• Baseline and periodic IOP measurement with pupillary dilation are mandatory when using any topical corticosteroid. 8, 1

If Concomitant Nasal Symptoms Exist

• Add intranasal corticosteroids (e.g., fluticasone furoate), which are as effective as oral or intranasal antihistamines for relieving ocular symptoms in patients with allergic rhinitis. 1

Critical Pitfalls to Avoid

• Do not prescribe ketorolac for allergic conjunctivitis when dual-action agents like olopatadine are available—ketorolac is inferior in efficacy and carries unnecessary corneal risks. 1, 6, 4
• Avoid oral first-generation antihistamines like Benadryl due to sedation, anticholinergic effects, and tear film drying; if systemic therapy is needed, use second-generation agents (cetirizine, fexofenadine, loratadine). 4
• Never use topical vasoconstrictors alone (naphazoline, tetrahydrozoline)—they only reduce redness without treating the underlying allergic inflammation and can cause rebound hyperemia after 10 days. 5, 1
• Mast-cell stabilizers used alone (cromolyn, lodoxamide) require several days to achieve effect and are unsuitable for acute symptom relief. 5, 1

Drug Interaction Safety Note

• The FDA label confirms ketorolac has been safely administered in conjunction with other ophthalmic medications including antibiotics, beta blockers, and mydriatics, so there is no pharmacologic contraindication to combining it with olopatadine. 6
• However, safety does not equal efficacy—the combination adds cost, complexity, and corneal risk without improving outcomes beyond olopatadine monotherapy. 2, 3